Epiderma is supplying its network with the newest VelaShape III
Safe non-surgical treatments
Discover the new generation VelaShape III unit, a state-of-the-art technology for the treatment of cellulite, body contouring and lymphatic drainage.
Representing an initial investment of roughly $85,000 per clinic, for a total exceeding $2 million, this move is part of an extensive equipment renewal plan introduced by Epiderma for 2019–2020.
The VelaShape III technology combines four proven technologies in one single treatment—infrared light, radiofrequency, massage rollers and suction. The simultaneous use of these technologies help in reducing localized fat deposits, contouring and firming treated areas. VelaShape III helps in treating heavy legs by promoting lymphatic drainage through massage, mechanical rollers and suction.
Based on the trials conducted by Epiderma, the Velashape III delivers significant benefits to clients such as treatments with little to no discomfort or pain, noticeably better results, and significantly shorter sessions and treatment plans.
Clinically tested for more than ten years with 5 millions independent treatments worldwide, Velashape is the only non-invasive treatment approuved by Health Canada and the FDA to reduce the appearance of cellulite and the circumference of the treated area. This technology has been the subject of the largest number of published studies on medical body remodeling devices with 97% satisfaction rate among those treated.